Docetaxel nanopolymeric - Samyang

Drug Profile

Docetaxel nanopolymeric - Samyang

Alternative Names: B 5927; Docetaxel-PNP; Nanoparticle docetaxel - Samyang; Nanopolymer docetaxel - Samyang; SYP-0709

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 20 Jul 2016 Docetaxel nanopolymeric is still in phase I development for Solid tumours in South Korea (Samyang Biopharmaceuticals Corporation pipeline, July 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 14 Oct 2014 Samyang plans a phase I trial for Solid tumours (late-stage disease) in South Korea (NCT02274610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top